Search bioRxiv⌕ Search

Biology subjects

Mathias, S. L.

Publications and source records attributed to Mathias, S. L..

3 recordsLinked to original sources

Deep Learning enabled discovery of kinase drug targets in Pharos

AO_SCPLOWBSTRACTC_SCPLOWWe use machine learning with standardized molecular structure and gene ontology data to predict ligand interactions for a set of human kinases. We realize this by leveraging information from the TCRD / Pharos database, developed and maintained within the Illuminating the Druggable Genome (IDG) project. Pharos collects relevant biochemical and clinically relevant information of a large set of biologically important (human) proteins from publicly available sources, including scientific publications as well as specialized databases. The 635 kinases listed in Pharos are classified into levels reflecting the relative amount and type of accumulated information. Importantly, molecular structure and Gene Ontology annotations are available for the entire set, but only 455 of the kinases have recorded ligand affinity data. We developed a deep neural network-based framework to predict the ligand affinity profile for kinases using generally available information (molecular structure and Gene Ontology annotations) as input. The input data is organized into a 2,770 - dimensional vector with binary entries. The output data are predicted affinity values for interactions between the respective kinase and possible ligands. To address the very large number of possible ligands (58,800) and the sparsity of available binding data, we organized the ligands into 5,275 clusters based on structural similarity measures. Our model framework is trained to predict likely interactions between kinases and these ligand clusters. We aim to identify sets of likely ligand partners associated with high predicted relative affinities for a given kinase. We measure performance by evaluating the efficiency in identifying known ligand partners for documented kinases that were not included in the training data. Our results indicate that our model framework can identify sets of ligands that will contain a significant fraction of the correct (known) ligand partners.

bioinformatics↗

TIGA: Target illumination GWAS analytics

Genome wide association studies (GWAS) can reveal important genotype-phenotype associations, however, data quality and interpretability issues must be addressed. For drug discovery scientists seeking to prioritize targets based on the available evidence, these issues go beyond the single study. Here, we describe rational ranking, filtering and interpretation of inferred gene-trait associations and data aggregation across studies by leveraging existing curation and harmonization efforts. Each gene-trait association is evaluated for confidence, with scores derived solely from aggregated statistics, linking a protein-coding gene and phenotype. We propose a method for assessing confidence in gene-trait associations from evidence aggregated across studies, including a bibliometric assessment of scientific consensus based on the iCite Relative Citation Ratio, and meanRank scores, to aggregate multivariate evidence. This method, intended for drug target hypothesis generation, scoring and ranking, has been implemented as an analytical pipeline, available as open source, with public datasets of results, and a web application designed for usability by drug discovery scientists, at https://unmtid-shinyapps.net/tiga/.

bioinformatics↗

Drug Target Ontology to Classify and Integrate Drug Discovery Data

BackgroundOne of the most successful approaches to develop new small molecule therapeutics has been to start from a validated druggable protein target. However, only a small subset of potentially druggable targets has attracted significant research and development resources. The Illuminating the Druggable Genome (IDG) project develops resources to catalyze the development of likely targetable, yet currently understudied prospective drug targets. A central component of the IDG program is a comprehensive knowledge resource of the druggable genome.\n\nResultsAs part of that effort, we have been developing a framework to integrate, navigate, and analyze drug discovery data based on formalized and standardized classifications and annotations of druggable protein targets, the Drug Target Ontology (DTO). DTO was constructed by extensive curation and consolidation of various resources. DTO classifies the four major drug target protein families, GPCRs, kinases, ion channels and nuclear receptors, based on phylogenecity, function, target development level, disease association, tissue expression, chemical ligand and substrate characteristics, and target-family specific characteristics. The formal ontology was built using a new software tool to auto-generate most axioms from a database while also supporting manual knowledge acquisition. A modular, hierarchical implementation facilitates development and maintenance and makes use of various external ontologies, thus integrating the DTO into the ecosystem of biomedical ontologies. As a formal OWL-DL ontology, DTO contains asserted and inferred axioms. Modeling data from the Library of Integrated Network-based Cellular Signatures (LINCS) program illustrates the potential of DTO for contextual data integration and nuanced definition of important drug target characteristics. DTO has been implemented in the IDG user interface Portal, Pharos and the TIN-X explorer of protein target disease relationships.\n\nConclusionsDTO was built based on the need for a formal semantic model for druggable targets including various related information such as protein, gene, protein domain, protein structure, binding site, small molecule drug, mechanism of action, protein tissue localization, disease association, and many other types of information. DTO will further facilitate the otherwise challenging integration and formal linking to biological assays, phenotypes, disease models, drug poly-pharmacology, binding kinetics and many other processes, functions and qualities that are at the core of drug discovery. The first version of DTO is publically available via the website http://drugtargetontology.org/, Github (https://github.com/DrugTargetOntology/DTO), and the NCBO Bioportal (https://bioportal.bioontology.org/ontologies/DTO). The long-term goal of DTO is to provide such an integrative framework and to populate the ontology with this information as a community resource.

bioinformatics↗